154 related articles for article (PubMed ID: 32940892)
1. Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes.
Witkowski M; Friebel J; Tabaraie T; Grabitz S; Dörner A; Taghipour L; Jakobs K; Stratmann B; Tschoepe D; Landmesser U; Rauch U
Cardiovasc Drugs Ther; 2021 Aug; 35(4):809-813. PubMed ID: 32940892
[TBL] [Abstract][Full Text] [Related]
2. Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes.
Witkowski M; Witkowski M; Saffarzadeh M; Friebel J; Tabaraie T; Ta Bao L; Chakraborty A; Dörner A; Stratmann B; Tschoepe D; Winter SJ; Krueger A; Ruf W; Landmesser U; Rauch U
Cardiovasc Diabetol; 2020 Feb; 19(1):20. PubMed ID: 32066445
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes.
Witkowski M; Tabaraie T; Steffens D; Friebel J; Dörner A; Skurk C; Witkowski M; Stratmann B; Tschoepe D; Landmesser U; Rauch U
Cardiovasc Diabetol; 2018 Feb; 17(1):34. PubMed ID: 29477147
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
5. Micro-RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor.
Witkowski M; Weithauser A; Tabaraie T; Steffens D; Kränkel N; Witkowski M; Stratmann B; Tschoepe D; Landmesser U; Rauch-Kroehnert U
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1263-71. PubMed ID: 27127202
[TBL] [Abstract][Full Text] [Related]
6. Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus.
El-Ghoroury EA; El-Din HG; Abdel-Kader M; Ragab S
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):7-13. PubMed ID: 18180609
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
Chen XM; Zhang WQ; Tian Y; Wang LF; Chen CC; Qiu CM
Cardiovasc Diabetol; 2018 Apr; 17(1):53. PubMed ID: 29636047
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA
Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
13. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
Derosa G; Franzetti I; Gadaleta G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Jun; 17(3):143-50. PubMed ID: 15334791
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Gupta M; Braga MB; Verma S
Can J Cardiol; 2008 Oct; 24(10):e65-9. PubMed ID: 18841263
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Wang J; Ciaraldi TP; Samad F
J Obes; 2015; 2015():291209. PubMed ID: 25861467
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
[TBL] [Abstract][Full Text] [Related]
18. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR
Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
[TBL] [Abstract][Full Text] [Related]
19. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
